To The Moon

$UnitedHealth(UNH)$

UnitedHealth Group (UNH) just had one of its worst single-day performances in recent history, plunging 23% in a single session following its Q1 earnings report and a dramatic cut to forward guidance.

The company now expects $26 to $26.50 in EPS for 2025, a shocking revision compared to analyst expectations of around $29.50 to $30 per share. No one saw this coming — not to this magnitude. And it’s rattling investors who once viewed UNH as one of the market’s safest large-cap plays.

For years, UnitedHealth has been perceived as a fortress stock — recession-resistant, relatively immune to macro shocks, tariffs, currency devaluation, and broader economic weakness. But that reputation took a serious hit this week.

So, in this breakdown, I’ll walk you through:

• What went wrong with UNH’s guidance

• A closer look at their business segments

• My fair value estimate based on realistic growth assumptions

• And finally, whether I think this drop is a buying opportunity or a trap in disguise

Earning Overview

Recent earnings miss and downward revision of its 2025 profit forecast, market sentiment has turned notably cautious. The company's stock experienced a significant decline, dropping over 22% in a single day—the steepest fall since 1998—after reporting first-quarter earnings that fell short of expectations and adjusting its 2025 earnings guidance to $26–$26.50 per share, down from the previous estimate of $29.50–$30.00.

Fundamental Analysis

UnitedHealth Group has two major operating segments:

1. UnitedHealthcare (insurance operations)

2. Optum (healthcare services and tech)

UnitedHealthcare handles insurance — the traditional core business. Margins are relatively modest, and growth is steady but not spectacular. Think of it as the cash cow.

Optum, on the other hand, is the crown jewel. It’s the high-growth, high-margin segment that’s driving long-term upside. It includes divisions like:

• OptumHealth – Care delivery and provider services

• OptumRx – Pharmacy benefits management

• OptumInsight – The most exciting one, in my opinion

Optum Insight is essentially UNH’s healthcare software & analytics business. It modernizes outdated hospital systems, streamlines billing, and implements scalable payment platforms. It had a $33 billion backlog in 2024, and that number has been rising every year.

What makes Optum so powerful is the margin profile. Operating margins are in the 8–10% range, well above what we see in the insurance side. If Optum continues to grow in mix, margins across the entire business could slowly expand.

So while the earnings cut was painful, Optum remains a structural growth engine. And in the long run, that may matter more than this year’s setback.

Guidance

A Track Record of Long-Term Growth

Let’s zoom out. UNH isn’t some speculative tech startup — it’s one of the most stable, consistent revenue machines in the S&P 500.

• Revenue has grown every single year since at least 2002.

• In 2002, they generated $25 billion in revenue.

• By 2025, they’re on pace for $450 billion.

That’s an 18x increase in just over two decades. Very few companies have accomplished this — especially with the level of stability UNH has shown along the way.

They’ve also been generous with shareholder returns:

• Buybacks: Historically, UNH has repurchased 5–6% of its market cap annually. Lately, it’s been closer to 1–2%, likely due to valuation concerns or strategic reinvestment.

• Dividends: The dividend has grown from just $0.03 in 2009 to a projected $8.80 in 2025 — a staggering growth rate.

Even though the dividend yield is only around 1.5%, the growth trajectory means yield-on-cost can rise rapidly for long-term investors.

UNH currently generates a 6% free cash flow yield, and has over $34 billion in cash. They’re in a strong financial position — with plenty of firepower to ramp up buybacks at these depressed levels, if management chooses to.

Free Cash Flow

UnitedHealth Group has shown strong free cash flow (FCF) performance, reflecting its solid financial position and ability to reinvest, return capital to shareholders, and weather industry pressures.

• Full-Year 2024: UNH generated approximately $20.7 billion in free cash flow, based on $24.2 billion in operating cash flow and $3.5 billion in capital expenditures.

• Trailing Twelve Months (TTM) as of March 2025: Free cash flow increased to about $24.86 billion, indicating ongoing strength in the company’s core operations.

• Quarterly Breakdown:

  Q4 2024: FCF came in around $1.46 billion, reflecting seasonal cash outflows.

  Q1 2025: FCF rebounded sharply to $4.56 billion, showing a solid start to the new fiscal year.

Free Cash Flow Yield & Valuation

• FCF Yield: Currently around 5.9%, which is considered attractive relative to market averages—indicating potential undervaluation or strong cash generation.

• Price-to-Free Cash Flow (P/FCF) Ratio: The P/FCF ratio sits just above 20, aligning with historical norms for a high-quality healthcare business like UNH.

In 2024, UnitedHealth returned over $16 billion to shareholders through a mix of dividends and share repurchases. This highlights the company’s commitment to shareholder returns and its strong balance sheet flexibility.

Risks and Challenges

1. Increased Medical Utilization

• Rising Costs: UNH is facing higher-than-expected medical costs, particularly in its Medicare Advantage business. Seniors are using more healthcare services, driving up expenses for the company.

• Margin Compression: Increased utilization leads to thinner margins, especially in a heavily regulated insurance environment where pricing flexibility is limited in the short term.

2. Medicare Advantage Uncertainty

• Regulatory Scrutiny: Medicare Advantage, one of UNH’s most profitable segments, is under pressure from potential reimbursement cuts and tightening regulations.

• Billing Practices Investigation: The Department of Justice is investigating UnitedHealth’s billing practices related to Medicare, which could lead to fines, legal costs, or operational restrictions if misconduct is found.

3. Cybersecurity Fallout

• Data Breach Impact: A recent cyberattack tied to Change Healthcare (a subsidiary of UNH) affected claims processing across the country, disrupting services for millions and potentially impacting revenues and reputation.

• Long-Term Reputation Risk: These incidents highlight vulnerabilities in the healthcare system and could erode trust among providers and patients.

4. Guidance Cut and Sentiment Shift

• Loss of “Safe Haven” Status: UNH was traditionally seen as a defensive, recession-resistant stock. The drastic cut in earnings guidance has shaken that perception.

• Investor Confidence: After years of consistent execution, a sudden earnings miss has shifted sentiment, prompting some investors to question management’s visibility and control over cost trends.

5. Valuation Compression

• Multiple Risk: Historically, UNH traded at a premium multiple (17–19x earnings), but a loss of confidence or further disappointments could compress that multiple toward historical lows, reducing upside.

• Limited Margin of Safety: At current prices, the stock may still not offer an attractive risk/reward setup unless earnings stabilize or growth re-accelerates.

Valuation

Let’s run a base-case DCF-style earnings valuation using conservative assumptions.

• Start with $26 EPS in 2025 (their own guidance)

• Apply 13% annual EPS growth through 2029 — in line with historical performance

  (For reference: EPS grew 10–15% annually over the past decade)

That gives us a 2029 EPS estimate of $42.39.

Historical Valuation Range:

• Mean P/E (2013–2024): 17x

• Current P/E: 19x

• Range: 9.5x (during COVID crash) to 25x

Scenario 1 – Best Case (19x Multiple):

• $42.39 × 19 = $805 fair value by 2029

• That’s ~78% upside from the current ~$450 price

• Annualized return = 12.3% CAGR

Scenario 2 – Fair Case (17x Multiple):

• $42.39 × 17 = $720 by 2029

• Only 60% upside = ~9.9% CAGR

That’s not bad — but it’s below my personal hurdle rate. I generally aim for a double every five years (~15% annualized return). To get that from UNH, you'd need to:

• Buy at $360 (on a 17x multiple)

• Or buy at $400 (on a 19x multiple)

So for me, $400 is the upper bound of what I’d consider “fair value”. Anything above that, and the margin of safety erodes too much.

Market sentiment

Analyst Ratings and Price Targets:

Despite the recent downturn, analysts maintain a generally positive outlook on UNH. According to MarketBeat, all 23 analysts covering the stock have issued "Buy" or "Strong Buy" ratings, with no "Hold" or "Sell" recommendations. The consensus 12-month price target stands at $632.85, suggesting a potential upside of approximately 38.75% from the current trading price.

Raymond James has adjusted its price target for UNH from $635.00 to $540.00 while maintaining a "Strong Buy" rating. This revision reflects a recalibration of earnings expectations, with the firm now estimating non-GAAP EPS for 2026 at $30.00, down about 10% from previous forecasts. ​

Market sentiment has been impacted by several factors beyond the earnings miss. These include increased medical costs for Medicare Advantage enrollees, a recent cyberattack affecting 200 million Americans, and a Department of Justice investigation into the company's Medicare billing practices.

Despite these challenges, some investors view the stock's decline as a potential buying opportunity, citing UnitedHealth's strong fundamentals and long-term growth prospects. The company's robust cash flow and history of shareholder returns through dividends and share repurchases contribute to this perspective.

The recent downturn in sentiment is tied to a few major concerns:

• Rising medical costs, especially in Medicare Advantage.

• A cyberattack that affected millions of patients.

• A Department of Justice investigation into Medicare billing practices.

These issues have raised questions about near-term profitability and regulatory risks. However, many investors still see UNH as a high-quality business with strong cash flow, an excellent track record of growth, and a history of returning capital to shareholders through dividends and buybacks.

Bottom Line:

Sentiment around UNH has clearly weakened in the short term, but many view the recent sell-off as potentially overdone. While regulatory and operational headwinds remain, the company's fundamentals, size, and diversification could support a recovery over time. For now, investors are watching closely to see how management navigates these challenges and whether the stock presents a buying opportunity at lower valuations.

Conclusion

UNH is a fantastic business. It has:

• One of the best operating histories in healthcare

• A strong balance sheet and massive cash pile

• Structural growth through Optum

• And a clear path to compounding earnings

But valuation matters.

Even after a 23% drop, the stock is not screamingly cheap. At $450, the upside over five years just isn’t compelling enough — not compared to other large-cap opportunities in today’s market. Stocks like Google and Amazon are trading at 17x operating cash flow, offering comparable or better growth with fewer headline risks.

So here’s my take:

• My buy zone for UNH is $360–$400 per share

• I’ve set a price alert at $400

• If it hits that level, I’ll re-evaluate for a potential entry

• Until then, I’m watching from the sidelines

This isn’t about panic — and it’s not about FOMO. It’s about discipline and waiting for the right price, not just a lower one. There will always be another opportunity, and this market is full of them.

If you’re a long-term holder and believe in UNH’s story, averaging in over time could make sense — especially if you’re focused on dividend growth. But for me personally, I’m waiting for a true value proposition before pulling the trigger.

Disclaimer: I want to make it clear that I am not a financial advisor, and nothing I say is intended to be a recommendation to buy or sell any financial instrument. Additionally, it's important to remember that there are no guarantees or certainties in trading or investing, and you should never invest money that you can't afford to lose.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub